Revenue
0 USD
2024 Q4 · USD
Fundies. English
NYMOX PHARMACEUTICAL CORPORATION
EDGARAnnual consolidated revenue for 2025: about USD 0, using the latest reported figures. The previous period, 2024, was about USD 0.
Latest quarter
Operating cash flow
-717 thousand USD
2024 Q4 · USD
Free cash flow
-717 thousand USD
2024 Q4 · USD
- Cash and cash equivalents
- 4.07 million USD Source
Exact value
4070000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- Not available
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-09-29.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 11 of 11 periods available· newest 2025-12-31
- Operating income: 11 of 11 periods available· newest 2025-12-31
- Net income: 7 of 11 periods available· newest 2025-12-31
- Operating cash flow: 11 of 11 periods available· newest 2025-12-31
- Capital expenditure: 9 of 11 periods available· newest 2025-12-31
- Total assets: 11 of 11 periods available· newest 2025-12-31
- Total liabilities: 11 of 11 periods available· newest 2025-12-31
- Current assets: 11 of 11 periods available· newest 2025-12-31
- Current liabilities: 9 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 7 of 11 periods available· newest 2021-12-31
- long term debt: No compatible figures in this window
- shares outstanding: No compatible figures in this window
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
USD 0Prior period
USD 0
–
Current period
USD 0
–
Exact inputs and evidence
0 − 0 = 0 USD
0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 217,000Prior period
−USD 4.49 million
–
Current period
−USD 4.28 million
–
Exact inputs and evidence
-4275000 − -4492000 = 217000 USD
-4492000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-4275000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 795,000Prior period
−USD 2.6 million
–
Current period
−USD 1.81 million
–
Exact inputs and evidence
-1806000 − -2601000 = 795000 USD
-2601000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-1806000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
−USD 1,000Prior period
USD 0
–
Current period
−USD 1,000
–
Exact inputs and evidence
-1000 − 0 = -1000 USD
0 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-1000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue USD 0
- Cost of revenue USD 0
- Operating expenses USD 3.68 million
- Other operating costs Derived USD 0
- Operating income −USD 3.68 million
- Tax, interest and other Derived USD 598,000
- Net income −USD 4.28 million
Cash
- Operating cash flow −USD 1.81 million
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2016 Not shown: operating income or net income is not reported.
- 2017 Not shown: operating income or net income is not reported.
- 2018 Not shown: operating income or net income is not reported.
- 2019 Operating loss: operating costs were 11,587% of revenue.
- 2020 Operating loss: operating costs were 234,500% of revenue.
- 2021 Not shown: operating income or net income is not reported.
- 2022 Not shown: operating income or net income is not reported.
- 2023 Not shown: operating income or net income is not reported.
- 2024 Not shown: operating income or net income is not reported.
- 2025 Not shown: operating income or net income is not reported.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2016 2016-01-01 – 2016-12-31 | 284000 | 13153000 Derived | -12869000 | Unavailable | Unavailable | -4504000 Derived | Source
|
| 2017 2017-01-01 – 2017-12-31 | 224000 | 13459000 Derived | -13235000 | Unavailable | Unavailable | Unavailable | Source
|
| 2018 2018-01-01 – 2018-12-31 | 299000 | 10940000 Derived | -10641000 | Unavailable | Unavailable | -7837000 Derived | Source
|
| 2019 2019-01-01 – 2019-12-31 | 116000 | 13441000 Derived | -13325000 | -163000 Derived | -13162000 | -7430000 Derived | Source
|
| 2020 2020-01-01 – 2020-12-31 | 5000 | 11725000 Derived | -11720000 | 18000 Derived | -11738000 | -10050000 Derived | Source
|
| 2021 2021-01-01 – 2021-12-31 | 0 | 12504000 Derived | -12504000 | 33000 Derived | -12537000 | -9826000 Derived | Source
|
| 2022 2022-01-01 – 2022-12-31 | 0 | 6652000 Derived | -6652000 | -76000 Derived | -6576000 | -5205000 Derived | Source
|
| 2023 2023-01-01 – 2023-12-31 | 0 | 8350000 Derived | -8350000 | 494000 Derived | -8844000 | Unavailable | Source
|
| 2024 2024-01-01 – 2024-12-31 | 0 | 4283000 Derived | -4283000 | 209000 Derived | -4492000 | -2601000 Derived | Source
|
| 2025 2025-01-01 – 2025-12-31 | 0 | 3677000 Derived | -3677000 | 598000 Derived | -4275000 | Unavailable | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 0 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2016 | Revenue | 284000 |
|
| 2017 | Revenue | 224000 |
|
| 2018 | Revenue | 299000 |
|
| 2019 | Revenue | 116000 |
|
| 2020 | Revenue | 5000 |
|
| 2021 | Revenue | 0 |
|
| 2022 | Revenue | 0 |
|
| 2023 | Revenue | 0 |
|
| 2024 | Revenue | 0 |
|
| 2025 | Revenue | 0 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
-100% 2021
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Year over year | -89.7% |
|
| 2017 | Year over year | -21.1% |
|
| 2018 | Year over year | 33.5% |
|
| 2019 | Year over year | -61.2% |
|
| 2020 | Year over year | -95.7% |
|
| 2021 | Year over year | -100% |
|
| 2022 | Year over year | No prior comparable period |
|
| 2023 | Year over year | No prior comparable period |
|
| 2024 | Year over year | No prior comparable period |
|
| 2025 | Year over year | No prior comparable period |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -234,400% 2020
Net margin -234,760% 2020
Free cash flow margin -201,000% 2020
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Operating margin | -4,531.3% |
|
| 2017 | Operating margin | -5,908.5% |
|
| 2018 | Operating margin | -3,558.9% |
|
| 2019 | Operating margin | -11,487.1% |
|
| 2020 | Operating margin | -234,400% |
|
| 2021 | Operating margin | Not reported |
|
| 2022 | Operating margin | Not reported |
|
| 2023 | Operating margin | Not reported |
|
| 2024 | Operating margin | Not reported |
|
| 2025 | Operating margin | Not reported |
|
| 2016-12-31 | Net margin | Not reported |
|
| 2017-12-31 | Net margin | Not reported |
|
| 2018-12-31 | Net margin | Not reported |
|
| 2019 | Net margin | -11,346.6% |
|
| 2020 | Net margin | -234,760% |
|
| 2021 | Net margin | Not reported |
|
| 2022 | Net margin | Not reported |
|
| 2023 | Net margin | Not reported |
|
| 2024 | Net margin | Not reported |
|
| 2025 | Net margin | Not reported |
|
| 2016 | Free cash flow margin | -1,585.9% |
|
| 2017 | Free cash flow margin | Not reported |
|
| 2018 | Free cash flow margin | -2,621.1% |
|
| 2019 | Free cash flow margin | -6,405.2% |
|
| 2020 | Free cash flow margin | -201,000% |
|
| 2021 | Free cash flow margin | Not reported |
|
| 2022 | Free cash flow margin | Not reported |
|
| 2023 | Free cash flow margin | Not reported |
|
| 2024 | Free cash flow margin | Not reported |
|
| 2025 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -1.8M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2016 | Operating cash flow | -4502000 |
|
| 2017 | Operating cash flow | -6206000 |
|
| 2018 | Operating cash flow | -7801000 |
|
| 2019 | Operating cash flow | -7430000 |
|
| 2020 | Operating cash flow | -10037000 |
|
| 2021 | Operating cash flow | -9820000 |
|
| 2022 | Operating cash flow | -5205000 |
|
| 2023 | Operating cash flow | -4057000 |
|
| 2024 | Operating cash flow | -2601000 |
|
| 2025 | Operating cash flow | -1806000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
USD -2.6M 2024
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2016 | Free cash flow | -4504000 |
|
| 2017 | Free cash flow | Unavailable |
|
| 2018 | Free cash flow | -7837000 |
|
| 2019 | Free cash flow | -7430000 |
|
| 2020 | Free cash flow | -10050000 |
|
| 2021 | Free cash flow | -9826000 |
|
| 2022 | Free cash flow | -5205000 |
|
| 2023 | Free cash flow | Unavailable |
|
| 2024 | Free cash flow | -2601000 |
|
| 2025 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
1,715.5% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Liabilities / assets | 111.8% |
|
| 2017 | Liabilities / assets | 227.8% |
|
| 2018 | Liabilities / assets | 13.3% |
|
| 2019 | Liabilities / assets | 37.2% |
|
| 2020 | Liabilities / assets | 50.6% |
|
| 2021 | Liabilities / assets | 135.1% |
|
| 2022 | Liabilities / assets | 129.7% |
|
| 2023 | Liabilities / assets | 606.1% |
|
| 2024 | Liabilities / assets | 1,135.9% |
|
| 2025 | Liabilities / assets | 1,715.5% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
0.06× 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2016 | Current assets / current liabilities | Not reported |
|
| 2017 | Current assets / current liabilities | 0.43× |
|
| 2018 | Current assets / current liabilities | 7.47× |
|
| 2019 | Current assets / current liabilities | 2.61× |
|
| 2020 | Current assets / current liabilities | 1.98× |
|
| 2021 | Current assets / current liabilities | 0.58× |
|
| 2022 | Current assets / current liabilities | 0.69× |
|
| 2023 | Current assets / current liabilities | 0.16× |
|
| 2024 | Current assets / current liabilities | 0.09× |
|
| 2025 | Current assets / current liabilities | 0.06× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2016 2016-01-01 – 2016-12-31 | Unavailable Not reported for this period. | −USD 4.5 million Exact valueExact value: -4502000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 2,000 Exact valueExact value: 2000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 4.5 million Calculation and evidence-4502000 − 2000 USD Exact free cash flow: -4504000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2017 2017-01-01 – 2017-12-31 | Unavailable Not reported for this period. | −USD 6.21 million Exact valueExact value: -6206000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2018 2018-01-01 – 2018-12-31 | Unavailable Not reported for this period. | −USD 7.8 million Exact valueExact value: -7801000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 36,000 Exact valueExact value: 36000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 7.84 million Calculation and evidence-7801000 − 36000 USD Exact free cash flow: -7837000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2019 2019-01-01 – 2019-12-31 | −USD 13.16 million Exact valueExact value: -13162000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 7.43 million Exact valueExact value: -7430000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 7.43 million Calculation and evidence-7430000 − 0 USD Exact free cash flow: -7430000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2020 2020-01-01 – 2020-12-31 | −USD 11.74 million Exact valueExact value: -11738000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 10.04 million Exact valueExact value: -10037000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 13,000 Exact valueExact value: 13000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 10.05 million Calculation and evidence-10037000 − 13000 USD Exact free cash flow: -10050000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2021 2021-01-01 – 2021-12-31 | −USD 12.54 million Exact valueExact value: -12537000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 9.82 million Exact valueExact value: -9820000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 6,000 Exact valueExact value: 6000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 9.83 million Calculation and evidence-9820000 − 6000 USD Exact free cash flow: -9826000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2022 2022-01-01 – 2022-12-31 | −USD 6.58 million Exact valueExact value: -6576000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 5.21 million Exact valueExact value: -5205000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 5.21 million Calculation and evidence-5205000 − 0 USD Exact free cash flow: -5205000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2023 2023-01-01 – 2023-12-31 | −USD 8.84 million Exact valueExact value: -8844000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 4.06 million Exact valueExact value: -4057000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable The mapped spending value is negative, so its direction is unclear. | Unavailable Capital expenditure has a negative mapped value; spending direction is unclear. |
| 2024 2024-01-01 – 2024-12-31 | −USD 4.49 million Exact valueExact value: -4492000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.6 million Exact valueExact value: -2601000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.6 million Calculation and evidence-2601000 − 0 USD Exact free cash flow: -2601000 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | −USD 4.28 million Exact valueExact value: -4275000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.81 million Exact valueExact value: -1806000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable The mapped spending value is negative, so its direction is unclear. | Unavailable Capital expenditure has a negative mapped value; spending direction is unclear. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
219 filings · 1,513 latest values · 1,510 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001018735, 1018735, NYMXF, edgar:1018735
Also known as NYMOX PHARMACEUTICAL CORP, NYMOX PHARMACEUTICAL CORPORATION, Nymox Pharmaceutical Corporation